explore -WSS

explore

author：Wikipedia 2025-10-02 11:08:15 - browse：6

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Covid hospitalizations on the rise, Humana says

focus

knowledge

WSS

Advances in CAR

Humana sues Biden admin over Medicare Advantage audit rule

Palantir health business leans on meeting customers’ needs

Petition to FDA: Get the lead out of consumer hair dyes

Listen: Biogen's potential pivot, & Illumina's next chapter

Iowa House, Senate pass 6

knowledge

explore

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

How the political right came to back psychedelics to treat trauma

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How to fix cancer clinical trials' diversity problem

Medicare details structure of new drug price negotiation program

Beach reads and more: STAT's 2023 summer book list

Bright Health sells Medicare Advantage business to Molina

Medicaid rebukes states for mistakenly disenrolling children

United colonoscopy coverage change 'may cost lives,' doctors say

It's time to get medical device identifiers over the finish line

entertainment

It's time to get medical device identifiers over the finish line

Illumina names Agilent executive as new CEO

所以，要说百度不是“套路王”，你能信?　　晓枫说，游走在科技与人文之间，新浪创事记、虎嗅、百度百家、砍柴网、搜狐、艾瑞、品途等专栏作者，联系请加个人微信angaoeng。

Weighted lottery helped low

Elizabeth Holmes on track for early release from her 11

Leqembi, other new Alzheimer’s drugs require better biomarkers

entertainment

focus

knowledge

focus

knowledge

explore

knowledge

entertainment

It's time to get medical device identifiers over the finish line

Illumina names Agilent executive as new CEO

所以，要说百度不是“套路王”，你能信? 晓枫说，游走在科技与人文之间，新浪创事记、虎嗅、百度百家、砍柴网、搜狐、艾瑞、品途等专栏作者，联系请加个人微信angaoeng。

Weighted lottery helped low

Elizabeth Holmes on track for early release from her 11

Leqembi, other new Alzheimer’s drugs require better biomarkers

entertainment

focus

knowledge

focus

所以，要说百度不是“套路王”，你能信?　　晓枫说，游走在科技与人文之间，新浪创事记、虎嗅、百度百家、砍柴网、搜狐、艾瑞、品途等专栏作者，联系请加个人微信angaoeng。